Thierry de Baere1, Stephen Plotkin2, Renee Yu2, Allison Sutter2, Yue Wu2, Gregory M Cruise2. 1. Department of Interventional Radiology, Gustave Roussy Cancer Center, Villejuif, France; UFR Médecine Le Kremlin-Bicêtre, Universite Paris-Sud XI, Le Kremlin Bicêtre, France. Electronic address: thierry.debaere@gustaveroussy.fr. 2. MicroVention, Tustin, California.
Abstract
PURPOSE: To compare in vitro properties of 4 drug-eluting embolic agents loaded with doxorubicin. MATERIALS AND METHODS: DC Bead (100-300 µm), LifePearl (200 µm), HepaSphere (30-60 µm), and Tandem (100 µm) microspheres were loaded with 40 mg/20 mL of doxorubicin per milliliter of microspheres. Loading, elution, diameter changes after loading, changes in the amount of doxorubicin loaded over 2 weeks in storage, and time in suspension were evaluated. RESULTS: All microspheres loaded > 99% doxorubicin within 1 hour. In vitro elution reached a plateau by 6 hours, with 30% ± 5, 21% ± 2, 8% ± 3, and 6% ± 0 of the loaded doxorubicin eluted for LifePearl, DC Bead, HepaSphere, and Tandem microspheres, respectively, with at least 1 statistically significant difference between at least 2 of the products in doxorubicin eluted at every time point. The times to elute 75% of the total released doxorubicin were 197, 139, 110, and 77 min for DC Bead, LifePearl, HepaSphere, and Tandem microspheres, respectively. The average diameters of LifePearl, DC Bead, and Tandem microspheres were reduced after loading by 24%, 20%, and 9%, respectively. After suspension in contrast medium, no changes were observed in doxorubicin loading over 2 wk. After loading, times in suspension were 8.4 min ± 0.2, 6.0 min ± 0.1, 3.1 min ± 0.2, and 2.9 min ± 0.3 for Tandem, LifePearl, DC Bead, and HepaSphere microspheres, respectively. CONCLUSIONS: Although drug-eluting embolic agents universally loaded doxorubicin within 1 hour, the elution amounts, rates of release, diameter shrinkage, and times in suspension varied by product.
PURPOSE: To compare in vitro properties of 4 drug-eluting embolic agents loaded with doxorubicin. MATERIALS AND METHODS: DC Bead (100-300 µm), LifePearl (200 µm), HepaSphere (30-60 µm), and Tandem (100 µm) microspheres were loaded with 40 mg/20 mL of doxorubicin per milliliter of microspheres. Loading, elution, diameter changes after loading, changes in the amount of doxorubicin loaded over 2 weeks in storage, and time in suspension were evaluated. RESULTS: All microspheres loaded > 99% doxorubicin within 1 hour. In vitro elution reached a plateau by 6 hours, with 30% ± 5, 21% ± 2, 8% ± 3, and 6% ± 0 of the loaded doxorubicin eluted for LifePearl, DC Bead, HepaSphere, and Tandem microspheres, respectively, with at least 1 statistically significant difference between at least 2 of the products in doxorubicin eluted at every time point. The times to elute 75% of the total released doxorubicin were 197, 139, 110, and 77 min for DC Bead, LifePearl, HepaSphere, and Tandem microspheres, respectively. The average diameters of LifePearl, DC Bead, and Tandem microspheres were reduced after loading by 24%, 20%, and 9%, respectively. After suspension in contrast medium, no changes were observed in doxorubicin loading over 2 wk. After loading, times in suspension were 8.4 min ± 0.2, 6.0 min ± 0.1, 3.1 min ± 0.2, and 2.9 min ± 0.3 for Tandem, LifePearl, DC Bead, and HepaSphere microspheres, respectively. CONCLUSIONS: Although drug-eluting embolic agents universally loaded doxorubicin within 1 hour, the elution amounts, rates of release, diameter shrinkage, and times in suspension varied by product.
Authors: Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu Journal: Adv Mater Date: 2019-06-06 Impact factor: 30.849
Authors: Andrew S Mikhail; Michal Mauda-Havakuk; Ayele H Negussie; Natalie Hong; Natalie M Hawken; Camella J Carlson; Joshua W Owen; Olga Franco-Mahecha; Paul G Wakim; Andrew L Lewis; William F Pritchard; John W Karanian; Bradford J Wood Journal: Int J Pharm Date: 2022-01-20 Impact factor: 6.510
Authors: Götz Richter; Boris Radeleff; Christian Stroszczynski; Philippe Pereira; Thomas Helmberger; Mark Barakat; Peter Huppert Journal: Cardiovasc Intervent Radiol Date: 2017-11-22 Impact factor: 2.740